علاج قِصَر القامة وفشل النمو عند الأطفال المصابين بمتلازمة تيرنر

DOI: 10.1093/ejendo/lvae050

Treatment may be offered from as young as 2 years of age in the following circumstances: evidence of growth failure (rate of growth below normal or declining), short stature, or likelihood of short stature.

GH treatment may be offered later, as long as epiphyses remain open.

We recommend a starting GH dose of 45-50 μg kg⁻¹ day⁻¹ or (1.3-1.5 mg m⁻² day⁻¹) in most instances, increasing to a maximum of 68 μg kg⁻¹ day⁻¹ (2.0 mg m⁻² day⁻¹) if response is suboptimal and/or adult height potential remains substantially compromised.

Maintenance of height percentile equivalent to, or greater than, the pre-treatment height percentile on a female population-based growth chart or increasing percentile on a TS-specific height chart, provides evidence of treatment effect.

We suggest generally maintaining IGF-I within the normal range for age, pubertal stage, and sex.